RBX to Reduce Risk of Vision Loss
diabetes-related eye problems, especially those who have moderate cases of
macular edema, may soon have a new drug available to them. A phase III clinical
trial has shown that a drug called RBX, for ruboxistaurin, may reduce the risk
of moderate vision loss and was well tolerated among participants.
When you have diabetic
macular edema, blood vessels that leak cause swelling in the part of the retina
that’s responsible for sharp central vision. RBX, taken by mouth, blocks the
action of an enzyme called protein kinase C beta, or PKC beta, which has been
linked to diabetic eye complications.
A larger trial is currently
being conducted. If it, too, shows that RBX is effective, the medication is
likely to become available to the population at large.
The PKC-Diabetic Retinopathy Study.